Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Therapeutic Drug Monitoring|February 23, 2018
Amiodarone Rifampicin Drug-Drug Interaction Management With Therapeutic Drug MonitoringThijs H Oude Munnink, Anna Demmer, Roel H J Slenter, et al.
Clinical Case Reports|November 24, 2021
Impact of malnourishment on the pharmacokinetics of acetaminophen and susceptibility to acetaminophen hepatotoxicityDaan Zillen, Kris L L Movig, Gert Kant, et al.
Clinical Neuropharmacology|June 19, 2009
Single dose of fluoxetine increases muscle activation in chronic stroke patientsHanneke Irene Berends, Juliette Nijlant, Michel van Putten, et al.
European Journal of Clinical Pharmacology|May 17, 2005
The impact of hospitalisation on the initiation and long-term use of benzodiazepinesRutger Stuffken, Rolf P van Hulten, Eibert R Heerdink, et al.
European Journal of Clinical Pharmacology|January 4, 2007
Influence of initial use of serotonergic antidepressants on antiparkinsonian drug use in levodopa-using patientsMaurits E L Arbouw, Kris L L Movig, Cees Neef, et al.
European Journal of Clinical Pharmacology|July 23, 2011
Dopamine agonists and ischemic complications in Parkinson's disease: a nested case-control studyMaurits E L Arbouw, Kris L L Movig, Henk-Jan Guchelaar, et al.
Clinical Drug Investigation|May 27, 2017
Decrease in Switches to 'Unsafe' Proton Pump Inhibitors After Communications About Interactions with ClopidogrelWillemien J Kruik-Kollöffel, Job van der Palen, Myrthe P P van Herk-Sukel, et al.
Psychopharmacology|October 17, 2009
Effect of apomorphine on cognitive performance and sensorimotor gating in humansArnt F A Schellekens, K P Grootens, C Neef, et al.
Pharmacology Research & Perspectives|January 25, 2017
Prescription behavior for gastroprotective drugs in new users as a result of communications regarding clopidogrel - proton pump inhibitor interactionWillemien J Kruik-Kollöffel, Job van der Palen, H Joost Kruik, et al.
Therapeutic Advances in Gastroenterology|September 14, 2023
Discontinuation of infliximab treatment in patients with inflammatory bowel disease who retransitioned to originator and those who remained on biosimilarRosanne W Meijboom, Helga Gardarsdottir, Matthijs L Becker, et al.
Pageof 3